Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Injection
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This study is Safety, Tolerability and Pharmacokinetic of Recombinant anti-IL-5 Humanized
Monoclonal Antibody injection in Healthy Subjects. There are 6 Groups as follows: 0.03mg/kg
(S1), 0.2mg/kg (S2), 1.0mg/kg (S3), 3.0mg/kg (S4), 5.0mg/kg (S5) and 7.5mg/kg (S6); and 2
subjects were included in the S1 group (both received study drugs); 10 subjects were included
in each of the S2 ~ S6 groups (of which 8 received study drugs and 2 received placebo).
Pharmacokinetics and Anti-drug antibody (ADA) data will be collected; Drug safety, tolerance,
efficacy and immunogenicity for healthy subjects will be evaluated.